Supreme Court denies leave in infliximab patent infringement action
On January 8, 2021, the Supreme Court of Canada denied leave to Janssen and Kennedy Trust (Docket No. 39099) with respect to the
Federal Court of Appeal’s decision remitting to the trial judge the reconsideration of issues of obviousness and anticipation (as previously reported).
Amgen seeks leave to appeal decision invalidating its filgrastim patent
As previously reported, the Federal Court of Appeal had dismissed Amgen’s appeal from a decision invalidating claims of a patent relating to filgrastim (Amgen’s NEUPOGEN and Pfizer’s biosimilar product NIVESTYM). On January 4, 2021, Amgen applied to the Supreme Court of Canada for leave to appeal (Docket No. 39530).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal challenging amended basket of comparator countries in PMPRB Regulations
On December 5, 2022, the Federal Court of Appeal (FCA) dismissed Innovative Medicines Canada (IMC) and sixteen innovative pharmaceutical companies’ appeal.Read More -
Federal Court rejects pre-trial determination of a question of law about the nature of the section 8 but-for world
As previously reported, the Federal Court found Janssen’s Canadian Patent No. 2,661,422 (422 patent) – which relates to treatment of prostate cancer in humans by co-administration of abiraterone aceta...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More